Molecular Partners AG (SIX: MOLN.SW) Stock Competitors & Peer Comparison
See MOLN.SW's competitors and their performance on the SIX and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for MOLN.SW and its SIX peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MOLN.SW | CHF 3.49 | +0.00% | 130.9M | -2.24 | -CHF 1.56 | N/A |
| LONN.SW | CHF 592.20 | +1.09% | 41.4B | 37.18 | CHF 15.93 | +0.84% |
| BANB.SW | CHF 77.40 | +0.00% | 5.8B | 38.93 | CHF 1.99 | +1.16% |
| MOR.SW | CHF 102.00 | +0.00% | 2.4B | -4.03 | -CHF 25.33 | N/A |
| IDIA.SW | CHF 5.55 | -0.89% | 1.5B | -6.41 | -CHF 0.87 | N/A |
| KURN.SW | CHF 21.52 | -4.19% | 848.7M | 118.90 | CHF 0.18 | N/A |
| BSLN.SW | CHF 64.60 | -1.52% | 799.5M | 30.60 | CHF 2.11 | N/A |
| NWRN.SW | CHF 12.54 | -0.32% | 260.9M | 18.57 | CHF 0.68 | N/A |
| SANN.SW | CHF 16.64 | +0.73% | 246.8M | -4.34 | -CHF 3.83 | N/A |
| RLF.SW | CHF 2.89 | +0.87% | 36.3M | -2.12 | -CHF 1.36 | N/A |
Stock Comparison
Lonza Group AG (SIX: LONN.SW)
MOLN.SW vs LONN.SW Comparison August 2026
Molecular Partners AG (SIX: MOLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOLN.SW stands at 130.9M. In comparison, LONN.SW has a market cap of 41.4B. Regarding current trading prices, MOLN.SW is priced at CHF 3.49 on the SIX, while LONN.SW trades at CHF 592.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOLN.SW currently has a P/E ratio of -2.24, whereas LONN.SW's P/E ratio is 37.18. In terms of profitability, MOLN.SW's ROE is -0.66%, compared to LONN.SW's ROE of -0.01%. Regarding short-term risk, MOLN.SW is less volatile compared to LONN.SW. This indicates lower risk in terms of short-term price fluctuations for MOLN.SW.Check LONN.SW's competition here
Bachem Holding AG (SIX: BANB.SW)
MOLN.SW vs BANB.SW Comparison August 2026
Molecular Partners AG (SIX: MOLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOLN.SW stands at 130.9M. In comparison, BANB.SW has a market cap of 5.8B. Regarding current trading prices, MOLN.SW is priced at CHF 3.49 on the SIX, while BANB.SW trades at CHF 77.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOLN.SW currently has a P/E ratio of -2.24, whereas BANB.SW's P/E ratio is 38.93. In terms of profitability, MOLN.SW's ROE is -0.66%, compared to BANB.SW's ROE of +0.10%. Regarding short-term risk, MOLN.SW is less volatile compared to BANB.SW. This indicates lower risk in terms of short-term price fluctuations for MOLN.SW.Check BANB.SW's competition here
MorphoSys AG (SIX: MOR.SW)
MOLN.SW vs MOR.SW Comparison August 2026
Molecular Partners AG (SIX: MOLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOLN.SW stands at 130.9M. In comparison, MOR.SW has a market cap of 2.4B. Regarding current trading prices, MOLN.SW is priced at CHF 3.49 on the SIX, while MOR.SW trades at CHF 102.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOLN.SW currently has a P/E ratio of -2.24, whereas MOR.SW's P/E ratio is -4.03. In terms of profitability, MOLN.SW's ROE is -0.66%, compared to MOR.SW's ROE of -1.84%. Regarding short-term risk, MOLN.SW is not fully comparable compared to MOR.SW. This indicates unavailable risk data in terms of short-term price fluctuations for MOLN.SW.Check MOR.SW's competition here
Idorsia Ltd (SIX: IDIA.SW)
MOLN.SW vs IDIA.SW Comparison August 2026
Molecular Partners AG (SIX: MOLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOLN.SW stands at 130.9M. In comparison, IDIA.SW has a market cap of 1.5B. Regarding current trading prices, MOLN.SW is priced at CHF 3.49 on the SIX, while IDIA.SW trades at CHF 5.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOLN.SW currently has a P/E ratio of -2.24, whereas IDIA.SW's P/E ratio is -6.41. In terms of profitability, MOLN.SW's ROE is -0.66%, compared to IDIA.SW's ROE of +0.27%. Regarding short-term risk, MOLN.SW is less volatile compared to IDIA.SW. This indicates lower risk in terms of short-term price fluctuations for MOLN.SW.Check IDIA.SW's competition here
Kuros Biosciences AG (SIX: KURN.SW)
MOLN.SW vs KURN.SW Comparison August 2026
Molecular Partners AG (SIX: MOLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOLN.SW stands at 130.9M. In comparison, KURN.SW has a market cap of 848.7M. Regarding current trading prices, MOLN.SW is priced at CHF 3.49 on the SIX, while KURN.SW trades at CHF 21.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOLN.SW currently has a P/E ratio of -2.24, whereas KURN.SW's P/E ratio is 118.90. In terms of profitability, MOLN.SW's ROE is -0.66%, compared to KURN.SW's ROE of +0.10%. Regarding short-term risk, MOLN.SW is less volatile compared to KURN.SW. This indicates lower risk in terms of short-term price fluctuations for MOLN.SW.Check KURN.SW's competition here
Basilea Pharmaceutica AG (SIX: BSLN.SW)
MOLN.SW vs BSLN.SW Comparison August 2026
Molecular Partners AG (SIX: MOLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOLN.SW stands at 130.9M. In comparison, BSLN.SW has a market cap of 799.5M. Regarding current trading prices, MOLN.SW is priced at CHF 3.49 on the SIX, while BSLN.SW trades at CHF 64.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOLN.SW currently has a P/E ratio of -2.24, whereas BSLN.SW's P/E ratio is 30.60. In terms of profitability, MOLN.SW's ROE is -0.66%, compared to BSLN.SW's ROE of +0.36%. Regarding short-term risk, MOLN.SW is less volatile compared to BSLN.SW. This indicates lower risk in terms of short-term price fluctuations for MOLN.SW.Check BSLN.SW's competition here
Newron Pharmaceuticals S.p.A. (SIX: NWRN.SW)
MOLN.SW vs NWRN.SW Comparison August 2026
Molecular Partners AG (SIX: MOLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOLN.SW stands at 130.9M. In comparison, NWRN.SW has a market cap of 260.9M. Regarding current trading prices, MOLN.SW is priced at CHF 3.49 on the SIX, while NWRN.SW trades at CHF 12.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOLN.SW currently has a P/E ratio of -2.24, whereas NWRN.SW's P/E ratio is 18.57. In terms of profitability, MOLN.SW's ROE is -0.66%, compared to NWRN.SW's ROE of +2.78%. Regarding short-term risk, MOLN.SW is less volatile compared to NWRN.SW. This indicates lower risk in terms of short-term price fluctuations for MOLN.SW.Check NWRN.SW's competition here
Santhera Pharmaceuticals Holding AG (SIX: SANN.SW)
MOLN.SW vs SANN.SW Comparison August 2026
Molecular Partners AG (SIX: MOLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOLN.SW stands at 130.9M. In comparison, SANN.SW has a market cap of 246.8M. Regarding current trading prices, MOLN.SW is priced at CHF 3.49 on the SIX, while SANN.SW trades at CHF 16.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOLN.SW currently has a P/E ratio of -2.24, whereas SANN.SW's P/E ratio is -4.34. In terms of profitability, MOLN.SW's ROE is -0.66%, compared to SANN.SW's ROE of +6.85%. Regarding short-term risk, MOLN.SW is less volatile compared to SANN.SW. This indicates lower risk in terms of short-term price fluctuations for MOLN.SW.Check SANN.SW's competition here
Relief Therapeutics Holding AG (SIX: RLF.SW)
MOLN.SW vs RLF.SW Comparison August 2026
Molecular Partners AG (SIX: MOLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOLN.SW stands at 130.9M. In comparison, RLF.SW has a market cap of 36.3M. Regarding current trading prices, MOLN.SW is priced at CHF 3.49 on the SIX, while RLF.SW trades at CHF 2.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOLN.SW currently has a P/E ratio of -2.24, whereas RLF.SW's P/E ratio is -2.12. In terms of profitability, MOLN.SW's ROE is -0.66%, compared to RLF.SW's ROE of -0.39%. Regarding short-term risk, MOLN.SW is less volatile compared to RLF.SW. This indicates lower risk in terms of short-term price fluctuations for MOLN.SW.Check RLF.SW's competition here
MindMaze Therapeutics Holding S.A. (SIX: MMTX.SW)
MOLN.SW vs MMTX.SW Comparison August 2026
Molecular Partners AG (SIX: MOLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOLN.SW stands at 130.9M. In comparison, MMTX.SW has a market cap of 29.9M. Regarding current trading prices, MOLN.SW is priced at CHF 3.49 on the SIX, while MMTX.SW trades at CHF 0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOLN.SW currently has a P/E ratio of -2.24, whereas MMTX.SW's P/E ratio is -0.40. In terms of profitability, MOLN.SW's ROE is -0.66%, compared to MMTX.SW's ROE of N/A. Regarding short-term risk, MOLN.SW is less volatile compared to MMTX.SW. This indicates lower risk in terms of short-term price fluctuations for MOLN.SW.Check MMTX.SW's competition here
Addex Therapeutics Ltd (SIX: ADXN.SW)
MOLN.SW vs ADXN.SW Comparison August 2026
Molecular Partners AG (SIX: MOLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOLN.SW stands at 130.9M. In comparison, ADXN.SW has a market cap of 5.3M. Regarding current trading prices, MOLN.SW is priced at CHF 3.49 on the SIX, while ADXN.SW trades at CHF 0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOLN.SW currently has a P/E ratio of -2.24, whereas ADXN.SW's P/E ratio is -0.62. In terms of profitability, MOLN.SW's ROE is -0.66%, compared to ADXN.SW's ROE of -1.31%. Regarding short-term risk, MOLN.SW is less volatile compared to ADXN.SW. This indicates lower risk in terms of short-term price fluctuations for MOLN.SW.Check ADXN.SW's competition here
Spexis AG (SIX: SPEX.SW)
MOLN.SW vs SPEX.SW Comparison August 2026
Molecular Partners AG (SIX: MOLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOLN.SW stands at 130.9M. In comparison, SPEX.SW has a market cap of 3.9M. Regarding current trading prices, MOLN.SW is priced at CHF 3.49 on the SIX, while SPEX.SW trades at CHF 0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOLN.SW currently has a P/E ratio of -2.24, whereas SPEX.SW's P/E ratio is -0.15. In terms of profitability, MOLN.SW's ROE is -0.66%, compared to SPEX.SW's ROE of N/A. Regarding short-term risk, MOLN.SW is less volatile compared to SPEX.SW. This indicates lower risk in terms of short-term price fluctuations for MOLN.SW.Check SPEX.SW's competition here
ObsEva S.A. (SIX: OBSN.SW)
MOLN.SW vs OBSN.SW Comparison August 2026
Molecular Partners AG (SIX: MOLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOLN.SW stands at 130.9M. In comparison, OBSN.SW has a market cap of 140.6K. Regarding current trading prices, MOLN.SW is priced at CHF 3.49 on the SIX, while OBSN.SW trades at CHF 0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOLN.SW currently has a P/E ratio of -2.24, whereas OBSN.SW's P/E ratio is -0.00. In terms of profitability, MOLN.SW's ROE is -0.66%, compared to OBSN.SW's ROE of -1.46%. Regarding short-term risk, MOLN.SW is less volatile compared to OBSN.SW. This indicates lower risk in terms of short-term price fluctuations for MOLN.SW.Check OBSN.SW's competition here
Cassiopea S.p.A. (SIX: SKIN.SW)
MOLN.SW vs SKIN.SW Comparison August 2026
Molecular Partners AG (SIX: MOLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOLN.SW stands at 130.9M. In comparison, SKIN.SW has a market cap of 0. Regarding current trading prices, MOLN.SW is priced at CHF 3.49 on the SIX, while SKIN.SW trades at CHF 35.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOLN.SW currently has a P/E ratio of -2.24, whereas SKIN.SW's P/E ratio is -28.13. In terms of profitability, MOLN.SW's ROE is -0.66%, compared to SKIN.SW's ROE of -1.27%. Regarding short-term risk, MOLN.SW is less volatile compared to SKIN.SW. This indicates lower risk in terms of short-term price fluctuations for MOLN.SW.Check SKIN.SW's competition here
Polyphor AG (SIX: POLN.SW)
MOLN.SW vs POLN.SW Comparison August 2026
Molecular Partners AG (SIX: MOLN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOLN.SW stands at 130.9M. In comparison, POLN.SW has a market cap of 0. Regarding current trading prices, MOLN.SW is priced at CHF 3.49 on the SIX, while POLN.SW trades at CHF 1.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOLN.SW currently has a P/E ratio of -2.24, whereas POLN.SW's P/E ratio is -0.46. In terms of profitability, MOLN.SW's ROE is -0.66%, compared to POLN.SW's ROE of -1.32%. Regarding short-term risk, MOLN.SW is less volatile compared to POLN.SW. This indicates lower risk in terms of short-term price fluctuations for MOLN.SW.Check POLN.SW's competition here